87 completed, 7 unknown, 3 withdrawn, 2 active not recruiting. 33 Phase 3, 17 Phase 2, 10 Phase 1, 6 Phase 4, 4 Not applicable.
Follow Rotavirus Infections: new trials by email Literature Review of Rotavirus Infections trials Research Report on Rotavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo - Rotavirus Infections | Phase 1 | Active not recruiting | Centers for Disease Control and Prevention | 50 | 2025-07-07 | 2026-03-05 |
| CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo - Rotavirus Infections | Phase 1 | Completed | Centers for Disease Control and Prevention | 50 | 2024-08-06 | 2026-05-26 |
| Phase II Clinical Trial of the Inactivated Rotavirus Vaccine IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0, 28 - Rotavirus Infections, Diarrhea | Phase 2 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 600 | 2023-10-20 | 2024-01-03 |
| Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine, High dose Recombinant Trivalent Subunit Rotavirus Vaccine, Placebo - Rotavirus Infections, Rotavirus Gastroenteritis | Phase 2 | Active not recruiting | MAXVAX Biotechnology Limited Liability Company | 1512 | 2023-01-08 | 2024-11-20 |
| A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy Rotavirus Vaccine - Vaccination, Rotavirus Infections | Unknown | Federico II University | 2000 | 2022-05-01 | 2022-03-17 | |
| Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection Low dosage IRV on a 0- and 28-day schedule, Medium dosage IRV on a 0- and 28-day schedule, High dosage IRV on a 0- and 28-day schedule - Rotavirus Infection | Phase 1 | Unknown | Chinese Academy of Medical Sciences | 32 | 2020-12-03 | 2020-12-10 |
| Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine - Infections, Rotavirus | Phase 3 | Completed | GlaxoSmithKline | 1351 | 2019-07-19 | 2022-03-10 |
| Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried), Placebo - Rotavirus Infection | Phase 3 | Completed | Limited Liability Company Pharm Aid | 100 | 2019-02-22 | 2021-09-05 |
| Evaluation of an Infant Immunization Encouragement Program in Nigeria All Babies Are Equal Initiative (conditional cash transfer program) - Tuberculosis, Diphtheria | Not applicable | Completed | GiveWell | 5187 | 2018-07-01 | 2020-03-31 |
| Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years. The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried), Placebo - Rotavirus Infections, Rotavirus Vaccines | Phase 3 | Completed | Limited Liability Company Pharm Aid | 40 | 2018-06-25 | 2021-09-08 |
| A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine RV3-BB, Placebo - Rotavirus Infections | Phase 2 | Completed | Murdoch Childrens Research Institute | 711 | 2018-06-15 | 2023-07-10 |
| Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam ROTAVAC® - Rotavirus Infections | Phase 3 | Unknown | Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products | 360 | 2018-02-08 | 2019-03-25 |
| SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance Sanitation - Rotavirus Infections, Environmental Enteric Dysfunction | Completed | London School of Hygiene and Tropical Medicine | 261 | 2017-10-05 | 2025-12-26 | |
| This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1280 | 2017-09-14 | 2020-12-29 |
| The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity Rotarix, dose 1, Rotarix, dose 2, Placebo (for Rotarix dose 2) - Rotavirus Infection, Vaccine Response Impaired | Phase 4 | Completed | University of Vermont | 220 | 2017-06-12 | 2020-08-04 |
| Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks HRV PCV-free liquid vaccine, Rotarix - Infections, Rotavirus, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1612 | 2016-10-27 | 2020-07-21 |
| Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007 Data collection - Infections, Rotavirus | Completed | GlaxoSmithKline | 1 | 2016-02-01 | 2018-03-12 | |
| Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study Rotarix®,, Rotarix®, with other routine vaccines, RotaTeq®, - Intussusception, Rotavirus Infections | Phase 4 | Completed | Children's Hospital Medical Center, Cincinnati | 144 | 2015-11-01 | 2018-07-12 |
| The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine - Rotavirus Infections, Intestinal Bacteria Flora Disturbance | Not applicable | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 63 | 2015-09-01 | 2017-07-25 |
Showing 20 of 102. Sign in to see all of them.
Gastroenteritis (19) · Diarrhea (7) · Intussusception (3) · Tetanus (3) · Adenoviridae Infections (2) · Caliciviridae Infections (2) · Infections (2) · Measles (2) · Pneumococcal Infections (2) · Tooth, Impacted (2) · Whooping Cough (2) · Yellow Fever (2) · Arenaviridae Infections (1) · Brucellosis (1)
RNA Virus Infections (102) · Reoviridae Infections (102) · Virus Diseases (102) · Infections (100) · Digestive System Diseases (23) · Gastrointestinal Diseases (22) · Pathological Conditions, Signs and Symptoms (8) · Bacterial Infections (7) · Bacterial Infections and Mycoses (7) · Signs and Symptoms (7) · Signs and Symptoms, Digestive (7) · Gram-Positive Bacterial Infections (5) · Gram-Negative Bacterial Infections (4) · Intestinal Diseases (4) · Central Nervous System Diseases (3)
RIX4414 vaccine (27) · Rotavirus Vaccines (14) · Data Collection (9) · RotaTeq (8) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (3) · nitazoxanide (3) · Appointments and Schedules (2) · Data Interpretation, Statistical (2) · Diphtheria-Tetanus-acellular Pertussis Vaccines (2) · Freeze Drying (2) · PHiD-CV vaccine (2) · Tetanus Toxoid (2) · 10-valent pneumococcal conjugate vaccine (1) · 13-valent pneumococcal vaccine (1) · Acetaminophen (1)
GlaxoSmithKline (61) · Merck Sharp & Dohme LLC (9) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Centers for Disease Control and Prevention (2) · Centro Pediatrico Albina de Patino (2) · Limited Liability Company Pharm Aid (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Romark Laboratories L.C. (2) · Butantan Institute (1) · Children's Hospital Medical Center, Cincinnati (1) · Chinese Academy of Medical Sciences (1) · Federico II University (1) · GiveWell (1) · Hillel Yaffe Medical Center (1) · Institut Pasteur du Cambodge (1)
United States (10) · China (7) · Finland (6) · India (4) · Panama (4) · South Africa (4) · South Korea (4) · Taiwan (4) · Belgium (3) · Brazil (3) · Colombia (3) · Dominican Republic (3) · Japan (3) · Spain (3) · Argentina (2)
Christina Rostad, MD (2) · Lauren Nolan, PA-C (2) · Mona Abu-Zekry, MD (2) · Yanxia Wang (2) · Alexander R Precioso, MD,PhD (1) · Alfredo Gilio, MD (1) · Alison Connor, PhD (1) · Andrea Lo Vecchio, MD, PhD (1) · Benjamin Lee, M.D. (1) · Carlos N Teran, M.D (1) · Caroline Quach-Thanh, MD, MSc (1) · Claude Flamand, Ph.D. (1)
PMID 16394298, PMID 21238572, PMID 25424932, PMID 27657348, PMID 33025558, PMID 16394299, PMID 16829296, PMID 18756184, PMID 19209092, PMID 20540778, PMID 20735858, PMID 21323176, PMID 21389149, PMID 21658240, PMID 22221511, PMID 22225699, PMID 22243622, PMID 22272750, PMID 22305197, PMID 22974466, PMID 23807360, PMID 24013441, PMID 24079716, PMID 24967217, PMID 25276665, PMID 26065919, PMID 26546262, PMID 26721823, PMID 26751375, PMID 26823540, PMID 27373141, PMID 27494163, PMID 27622162, PMID 27662551, PMID 27714677, PMID 27895844, PMID 28140752, PMID 28778611, PMID 29564996, PMID 30335570, PMID 31607603, PMID 33847298, PMID 34788488, PMID 38796326, PMID 39339964, PMID 42733081
2015 (4), 2016 (2), 2018 (1), U01AI053719 (1)